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Abstract
Objective—To assess the performance of a hemolytic uremic syndrome (HUS) severity score
among children with Shiga toxin-producing Escherichia coli (STEC) infections and HUS by
stratifying them according to their risk of adverse events. The score has not been previously
evaluated in a North American acute care setting.

Author Manuscript

Study design—We reviewed medical records of children <18 years old infected with STEC and
treated in one of 38 participating EDs in North America between 2011 and 2015. The HUS
severity score [hemoglobin (g/dL) plus two-times serum creatinine (mg/dL)] was calculated using
first available laboratory results. Children with scores >13 were designated as high-risk. We
assessed score performance to predict severe adverse events (ie, dialysis, neurologic complication,
respiratory failure and death) using discrimination and net benefit (i.e. threshold probability), with
subgroup analyses by age and day-of-illness.
Results—A total of 167 children had HUS, of whom 92.8% (155/167) had relevant data to
calculate the score; 60.6% (94/155) experienced a severe adverse event. Discrimination was
acceptable overall (AUC 0.71, 95% CI 0.63, 0.79) and better among children <5 years old (AUC
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0.77, 95% CI 0.68, 0.87). For children <5 years, greatest net benefit was achieved for a threshold
probability >26%.
Conclusions—The HUS severity score was able to discriminate between high- and low-risk
children <5 years old with STEC-associated HUS at a statistically acceptable level; however, it did
not appear to provide clinical benefit at a meaningful risk threshold.
Keywords
hemolytic uremic syndrome; prognostic index; stx1; stx2

Author Manuscript

Children with Shiga toxin-producing Escherichia coli (STEC) may progress to develop
hemolytic uremic syndrome (HUS),1, 2 which is characterized by azotemia or renal failure,
microangiopathic hemolytic anemia, and thrombocytopenia.3 Though a subset of STEC
infections are devastating,4, 5 most resolve without significant complications. Emerging
approaches such as early-in-illness intravascular volume expansion6, 7 may have the
potential to alter the disease trajectory. Therefore, early diagnosis and risk stratification of
STEC-infected children at the first point-of-contact may indicate the need for closer
monitoring for disease evolution and in the future such approaches may enable the provision
of therapeutic interventions to improve outcomes.
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Although STEC infections are rarely confirmed during an initial healthcare encounter due to
the need to obtain a stool specimen and perform diagnostic testing, rapid molecular
multiplex polymerase chain reaction assays are increasingly being employed in high-income
countries.8 Simultaneously, given that nearly one-in-five children with high-risk STEC
infections (i.e. Stx2-producing strains of STEC) develop HUS and its associated
complications,9 institutions are increasingly adopting more standardized approaches to
baseline and ongoing laboratory monitoring.10 These evolving strategies have highlighted
the importance of being able to identify high-risk children to facilitate the selective
monitoring and the provision of interventions to improve outcomes.
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The ItalKid-HUS Network proposed an HUS severity score to predict severe adverse events
in children with STEC-related thrombotic microangiopathy referred to tertiary HUS
nephrology centers in Northern Italy.11 They proposed that severity could be predicted by
the following equation: [(Hemoglobin in g/dL) + (serum creatinine in mg/dL [ISP]× 2)].11 A
cut-point of 13 identified those at high risk of severe adverse events with adequate
discrimination [i.e. area under the curve (AUC) = 0.75].11 However, the score was applied to
a high-risk population and initial estimates of prognostic model performance are often
overly optimistic.12 Our primary objective was to apply the ItalKID-HUS Network HUS
severity score to children with STEC infections who developed HUS, who were enrolled in
our pediatric emergency department (ED)-based study. As a secondary objective, we
explored the performance of the severity score among all children with STEC, prior to HUS
onset, to determine the score’s potential for use earlier in illness.
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Methods
For this retrospective study, participating sites were members of the Pediatric Emergency
Medicine Collaborative Research Committee (PEMCRC) and/or Pediatric Emergency
Research Canada (PERC).13 Study participants were children <18 years with microbiologic
evidence of STEC infection, who visited one of 38 participating EDs in the United States
and Canada between January 1, 2011 and December 31, 2015. Clinical findings, laboratory
results, interventions, and complications from the ED visit, subsequent ED visits within 30
days, and inpatient data were extracted through chart review. The study received ethics
approval at all institutions.13
Cohort Definitions

Author Manuscript

For our primary objective, we defined the HUS cohort as participants with microbiologic
evidence of STEC infection who met HUS criteria at any ED visit (i.e. index or follow-up)
or during hospitalization. For the secondary objective, we defined the STEC cohort as
participants with microbiologic evidence of STEC infection that had laboratory (i.e.
hemoglobin and serum creatinine) testing performed and neither presented with nor
developed HUS (Figure 1; available at www.jpeds.com). A child was considered to have
HUS if, at any point in time, their platelets were <150,000/mm3 (<150 x 109/L), hematocrit
was <30% (<0.3), and serum creatinine concentration was above the upper limit of normal
for age.14 We excluded participants whose serum hemoglobin and creatinine concentrations
were not available.
Outcomes
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As not all outcomes from the ItalKid-HUS Network study were available in our cohort, we
focused on short-term outcomes that would be most applicable to the acute care and early
decision-making context. An STEC-associated severe adverse event was defined by the
initiation of renal replacement therapy, occurrence of a severe neurologic event (i.e. seizure
or stroke), respiratory failure (i.e. intubation), or death. Patient-specific indications for
utilizing interventions were not recorded.
HUS Severity Score
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As employed in the ItalKid-HUS Network study,11 we calculated the severity score as the
sum of the serum hemoglobin (g/dL) plus double the serum creatinine (mg/dL)
(Supplementary Methods). Scores for participants in the HUS cohort were based on
laboratory tests closest to, or on the day of development of HUS, but before dialysis
commenced. Scores for participants in the STEC cohort were based on first-available
laboratory collections. All serum creatinine and hemoglobin values used for score
calculation were collected during an ED visit. Scores were dichotomized into high (>13) and
low (≤13) risk groups per the ItalKid-HUS Network study.11 We excluded participants
whose serum hemoglobin and creatinine concentrations were not available.
Statistical Analyses
The severity score was analyzed within the HUS and STEC cohorts using discrimination and
decision curve analysis (DCA). DCA is an approach to evaluating prediction models that
J Pediatr. Author manuscript; available in PMC 2022 May 01.
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balances trade-offs in clinical decision making.15 For STEC-associated severe adverse
events, we measured discrimination by sensitivity, specificity, receiver operating
characteristics (ROC) curves, and AUC. An AUC >0.7 was a priori categorized as
acceptable.16
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In the context of STEC infection, although treatment options are currently limited, early
recognition of disease progression is vital to avoid children presenting with advanced renal
failure and its associated complications (eg, electrolyte abnormalities, hypertension). There
is also observational study evidence pointing towards benefits associated with early
intravascular volume expansion17, 18 and other candidate interventions are undergoing
evaluation.19 We used DCA to compare the net benefit of different clinical approaches to
managing STEC patients; i.e. treating only patients the HUS severity score determines to be
at high risk, treating all patients, and not treating any STEC patients. Net benefit was
measured along a spectrum of risk strata (i.e. threshold probabilities)15, which is the risk
level at which a clinician would treat to avoid one adverse event. For example, a threshold
probability of 10% means that if a child has a 10% risk of a severe adverse outcome, the
clinician would opt to treat. This method introduces the clinical context to the evaluation of
prognostic indices and provides guidance to physicians with varying willingness for
intervention. We identified the threshold probability levels for which the score provided a
greater net benefit compared with the alternative approaches.15
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In both cohorts, we conducted subgroup analyses by age, a priori specified as <5, 5 to <10,
and ≥10 years (Supplementary Methods).20 In the STEC cohort, we also analyzed score
performance by day of illness, ≤3 days or >3 days to determine the applicability of the score
to an acute care setting. Not all children with STEC infections are hospitalized. We did not
extend the day-of-illness analysis to the HUS cohort because children identified with HUS
would generally receive hospitalization on the day of diagnosis. If a child had serum
creatinine and hemoglobin levels measured in the first three days of their illness, the first
measure recorded was used to calculate a score, and the child was included in the ≤3 days of
illness analysis. If a child had the necessary laboratory values measured after day 3 of their
illness and HUS had not yet developed, the first values recorded on day 4 or after were used
to calculate a score for inclusion in the >3 days of illness analysis. If a child had the
necessary labs measured both within and after 3 days of illness, they were included in both
day-of-illness analyses.
Analyses were performed using SPSS software (Version 25.0, IBM Corp.; Armonk, NY).

Results
Author Manuscript

In total, 927 children with microbiologically confirmed STEC were identified, 167 (18.0%)
of whom met criteria for HUS; 92.8% (n=155) of children who developed HUS were
included in the analysis of the HUS cohort (Figure 1). The HUS cohort had a mean score of
14.5 and a standard deviation of 3.3 (Figure 2). The remaining 7.2% (n=12) lacked sufficient
laboratory data to calculate the severity score. The STEC cohort included 626 children and
excluded 260.
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Of participants with HUS, 60.6% (94/155) had a severe adverse event, including neurologic
complications in 26 (16.8%) and death in 2 (1.3%) (Table I; available at www.jpeds.com).
Of the 26 children with neurologic complications, 23 (88.5%) received dialysis. The score
classified 118 (76.1%) children as high-risk (Appendix 2, Table 1; available at
www.jpeds.com).
Discrimination—For predicting the occurrence of at least one severe adverse event, the
HUS severity score had an overall acceptable discrimination (AUC 0.71; 95% CI 0.63, 0.79)
and sensitivity (89.4%, 95% CI 81.3%, 94.8%) (Table 2 and Figure 3, A). Stratifying by age,
discrimination was greatest for children <5 years old (AUC 0.77; 95% CI 0.68, 0.87), with
sensitivity of 86.8% (95% CI 74.7%, 94.5%) and specificity of 56.8% (95% CI 39.5%,
72.9%). Discrimination was greatly attenuated for children ≥10 years of age.

Author Manuscript

Net Benefit for Children <5 Years—The DCA for children <5 years of age showed that
above a threshold probability of 26%, the highest net benefit is achieved by treating those
with HUS severity score >13 (Figure 4, A). Clinicians wanting to treat at lower probabilities
of a severe adverse event would find the greatest net benefit in a treat-all approach.
Extension to the STEC Cohort
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Severe adverse events occurred in 11.8% (74/626) of children with STEC who did not have
HUS at initial presentation (Table 1). Sensitivity (89.2%; 95% CI 79.8%, 95.2%) was
comparable with that of the HUS cohort, but specificity (19.7%; 95% CI 16.5%, 23.3%) was
lower (Table 2). The overall AUC for this group was poor (AUC 0.58; 95% CI 0.51, 0.65)
but was acceptable for children <5 years old (AUC 0.75; 95% CI 0.66, 0.84) (Figure 3, B).
DCA for those <5 years old showed the highest benefit is achieved using the HUS severity
score between threshold probabilities of 6% and 22% (Figure 4, B). To justify a treat-none
approach, clinicians would require a threshold probability of >22%, corresponding to a
willingness to treat 4 or fewer children to prevent one severe event.
Day of Illness—There were 292 children with serum creatinine and hemoglobin measured
on day ≤3 of illness, and 352 whose laboratory tests were performed on or after day four of
illness. The score had the highest AUC when calculated using laboratory values measured on
day 4 of illness or after among children <5 years old (AUC 0.86; 95% CI 0.79, 0.93)
(Appendix 2, Table 2).

Discussion
Author Manuscript

This study evaluates the HUS severity score, which was developed in a tertiary care
nephrology center, in an outpatient setting, to determine whether it can be adopted into
practice in this setting as published. In our study population, the score had an overall high
sensitivity (89%), which was offset by poor specificity (44%), yielding an AUC of 0.71.
Discrimination was greater for children aged <5 years (AUC 0.77). Although the AUC
showed statistical adequacy of distinguishing high- from low-risk children, our DCA
analysis suggested that the clinical utility of the score may be limited in children <5 years of
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age with HUS. The score only yielded greater net benefit than a treat-all approach if a
clinician would be unwilling to intervene until a child had at least a 26% probability of
experiencing a severe adverse event. If a child already has HUS, we find it unlikely many
clinicians would wait till there is a one in 4 chance of a severe adverse event before acting,
making a treat-all approach more beneficial in our population.

Author Manuscript

If a child is at high-risk of a severe adverse outcome, clinicians may consider several
interventions, including admitting the child for observation and close laboratory monitoring
or even intravascular volume expansion. Although there is some evidence that intravenous
volume expansion17, 18 and avoidance of hemoconcentration6 may improve outcomes,7 there
is not yet consensus on this approach and there exists the potential risk of fluid overload.21
Nonetheless, our DCA provides insights as to whether use of a severity score would aid in
clinical decision-making regarding whether to utilize a more interventional approach. For
example, a clinician may be willing to admit a child with even a small risk (e.g. 5%) of a
severe adverse outcome, because the drawbacks of admission are minimal in comparison
with the consequences of a seizure or death. However, the same clinician may be cautious
when it comes to aggressive volume expansion and willing to act only if a child had at least
a 20% risk of a severe adverse outcome.

Author Manuscript

The use of threshold probabilities has been explained in terms of the number of patients a
clinician would be willing to treat to avoid one undesirable outcome. 22 Following this logic,
in the context of STEC infection, a 5% threshold probability would correspond to a
willingness to admit 20 children to prevent 1 child from suffering a severe adverse event
under observation or treatment. In a recently conducted survey, pediatric emergency
medicine physicians and nephrologists stated they would be willing to admit a median of 25
children to prevent HUS-associated dialysis in one child.23 Given that the threshold
probability at which the HUS severity score yielded the highest benefit was 26%, and that
the surveyed clinicians would treat above a risk of 4%,23 a treat-all approach would be more
beneficial than using the HUS severity score in children with HUS. However, the threshold
probabilities of some clinicians may differ.
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Although Ardissino et al identified the score cutoff of 13 empirically,11 an application of the
score in Argentina yielded an optimal cutoff of 12.6.24 Our goal was to determine whether
the score, as published, could be applied by ED or other front-line clinicians. Given the
relative rarity of STEC-associated HUS, individual physicians cannot conduct their own
studies to determine their setting’s optimal cutoff, so the cutoff value, like the score itself,
must be generalizable. Our DCA results suggest that it may not be, because it does not
provide clinical benefit at a reasonable threshold probability. Future studies should consider
alternative cutoffs to optimize both discrimination and net benefit. Application in settings
where children with HUS first contact the healthcare system, such as the ED, should be
considered. Incorporating demographic factors (e.g. age)13 into prognostic index design
would accommodate individual patient features, rather than relying on laboratory values
alone. For example, an alternative HUS risk score was recently developed, which stratifies
patient risks based on features such as age, presenting symptoms and location.25
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The reduced performance of the severity score in our HUS cohort relative to the derivation
study11 is not surprising. Prognostic indices are often over-fit to the data from which they
were developed, and performance metrics should be adjusted for the resulting ‘optimism’.12
Additionally, several differences between the ItalKid-HUS Network study and our own,
preclude a true external validation of the HUS severity score. They classified all children
with microangiopathy as having HUS.11 We used an alternate, more commonly accepted
definition of HUS based on the triad of anemia, thrombocytopenia and renal insufficiency.26
Long-term outcomes were not available for our cohort; we instead used several in-hospital
severe adverse outcomes that clinicians may be concerned about averting. Our cohort was
also older on average, which may explain the poorer performance in children 5 and older.
Younger children have lower serum creatinine at baseline, and this measure may be less
sensitive in older children with higher baseline levels. Additionally, nearly half of the
children in the ItalKid-HUS Network study received early volume expansion,11 which may
have averted some of the severe adverse outcomes they were measuring and artificially
lowered their specificity. This treatment anecdotally was routinely used at two of the 38
hospitals in our study, likely introducing little bias but also making our study less
comparable with the derivation study.
We did not examine our data as a function of STEC genotype. The performance of the HUS
severity score could differ for STEC expressing different sets of Shiga toxins. STEC that do
not encode Shiga toxin 2 have little, if any, likelihood of causing HUS, and the virulence of
those that encode Shiga toxin 2 is attenuated if genes encoding Shiga toxin 1 are also
present.25, 27
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For exploratory purposes, we applied the score to STEC-infected children without, or prior
to, development of HUS. In this group, although discrimination was poor overall (AUC
0.58), it was acceptable among children <5 years of age (AUC 0.75). The greatest net benefit
was obtained by using the score between threshold values of 6% and 22%, a range that may
be appropriate for several clinical decisions. Discrimination improved when scores were
calculated from laboratory values obtained later in the disease course (AUC 0.86). For
children with STEC without HUS, pediatric emergency medicine physicians and
nephrologists were inclined to treat a median of ten children to prevent one case of HUS (i.e.
when risk is above 10%).23 We found that at this risk threshold, the HUS severity score had
the highest net benefit in children <5 years old in our STEC cohort. Although our results
therefore suggest that the score could be useful prior to the development of HUS, the score
relies on serum creatinine concentration, which may not be elevated at this stage of illness.
Similarly, hemoconcentration might evolve later in the pre-HUS interval, as capillary leak
develops. Additionally, 29% of children in the STEC cohort were excluded as they did not
have sufficient laboratory testing performed. Although there were limitations to this
exploratory analysis, and the HUS severity score was not designed for children without
HUS, we believe its performance after the third day of illness, particularly, warrants further
study.
The HUS severity score has the potential to help guide care in the outpatient setting,
particularly as rapid molecular diagnostics become widespread. Although the score
discriminated best between high- and low-risk children <5 years old with HUS on a
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statistical level, it had limited clinical benefit, as a greater net benefit than a treat-all
approach was only achieved when the risk of a severe adverse event exceeds 26%. Further
refinement of the score may be necessary prior to broad clinical application, including
extension to children with STEC but without HUS.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Area under the curve
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Chronic kidney disease
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Decision curve analysis

ED

Emergency department
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Hemolytic uremic syndrome
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Figure 1. Patient cohorts and definitions.

Of 927 participants with microbiologically confirmed STEC, 664 had adequate clinical
information to calculate severity scores. They were binned into STEC (n=626), and/or HUS
(n=155) cohorts. Children may have been included in both cohorts.
Abbreviations: ED, emergency department; HUS, hemolytic uremic syndrome; STEC, Shiga
toxin-producing Escherichia coli
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Figure 2.

Distribution of HUS severity scores in the HUS cohort, with the frequency of STECassociated severe adverse events in each score. The score was right skewed with a mean of
14.5 (SD of 3.3). Percentages denote the proportion of patients with severe adverse events.
Abbreviations: HUS, hemolytic uremic syndrome; STEC, Shiga toxin-producing

Escherichia coli
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Figure 3. ROC curves for the HUS severity score in predicting any severe adverse event.

(A) In the HUS cohort, the AUC was 0.71 (95% CI 0.63, 0.79) for all ages and 0.77 (95% CI
0.68, 0.87) for those <5 years old. (B) In the STEC cohort, overall, the AUC was 0.58 (0.51,
0.65), and for those <5 years old, the AUC was 0.75 (0.66, 0.84).
Abbreviations: AUC, area under the curve; HUS, hemolytic uremic syndrome; ROC,
receiver operating characteristics; STEC, Shiga toxin-producing Escherichia coli

Author Manuscript
Author Manuscript
J Pediatr. Author manuscript; available in PMC 2022 May 01.

Lin et al.

Page 16

Author Manuscript
Author Manuscript

Figure 4. Decision curve analysis.

Net benefit is shown as a function of the risk of a severe adverse event that a clinician will
tolerate (i.e. threshold probabilities) when deciding to treat. (A) For patients <5 years old in
the HUS cohort, the HUS severity score had the greatest net benefit above a threshold of
26% (i.e. a clinician would treat once the probability of a severe adverse event reaches 26%
in those treated). For clinicians who would want to treat at lower threshold probabilities, a
treat-all approach had the greatest net benefit. (B) In the STEC cohort, the greatest net
benefit is achieved for children <5 years old with the HUS severity score when clinicians
would treat patients whose probability of a severe adverse event is 6-22%.
Abbreviations: HUS, hemolytic uremic syndrome; STEC, Shiga toxin-producing

Escherichia coli
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Demographic information and frequency of outcomes in the overall and individual cohorts.
Overall Cohort

HUS Cohort

STEC Cohort

Characteristics (median (IQR) or n(%))
Number of participants

927

155

626

6.0 (2.8, 11.0)

4.4 (2.4, 7.3)

6.4 (3.4, 11.7)

490 (52.9%)

74 (47.7%)

319 (51.0%)

13.4 (12.3, 14.6)

12.5 (10.0, 14.3)

13.6 (12.5, 14.7)

134.0 (123.0, 146.0)

125.0 (100.0, 143.0)

136.0 (125, 147)

0.45 (0.31, 0.64)

0.64 (0.37, 1.50)

0.42 (0.30, 0.60

39.8 (27.4, 56.5

56.5 (32.7, 132.6)

37.1 (26.5, 53.0)

100 (10.8%)

94 (60.6%)

74 (11.8%)

Need for dialysis

94 (10.1%)

89 (57.4%)

69 (11.0%)

Neurologic complications (seizure, stroke)

28 (3.0%)

26 (16.8%)

23 (3.7%)

Respiratory failure

26 (2.8%)

26 (16.8%)

22 (3.5%)

Death

2 (0.2%)

2 (1.3%)

2 (0.3%)

28 (3.0%)

26 (16.8%)

23 (3.7%)

Age (year)
Male gender
Hemoglobin (g/dL)
Hemoglobin (g/L)

a

a

Serum creatinine (mg/dL)

a

Serum creatinine (micromol/L)

a

Author Manuscript

Outcomes
Any severe adverse event

Neurologic complications and/or death

Abbreviations: IQR, inter-quartile range; HUS, hemolytic uremic syndrome; STEC, Shiga toxin-producing Escherichia coli

a

data available for 664 patients.
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Sensitivity and specificity for severe adverse events, stratified by age group in the HUS and STEC cohorts.
Age group (years)

Sensitivity (%) (95% CI)

Specificity (%) (95% CI)

AUC (95% CI)

HUS Cohort
Overall

89.4 (81.3, 94.8)

44.3 (31.5, 57.6)

0.71 (0.63, 0.79)

0 to <5

86.8 (74.7, 94.5)

56.8 (39.5, 72.9)

0.77 (0.68, 0.87)

≥5 to <10

93.9 (79.8, 99.3)

35.3 (14.2, 61.7)

0.71 (0.56, 0.86)

≥10

87.5 (47.3, 99.7)

0.0 (0.0, 41.0)

0.57 (0.25, 0.89)

Overall

89.2 (79.8, 95.2)

19.7 (16.5, 23.3)

0.58 (0.51, 0.65)

0 to <5

87.2 (72.6, 95.7)

40.7 (34.1, 47.6)

0.75 (0.66, 0.84)

≥5 to <10

92.9 (76.5, 99.1)

12.2 (7.4, 18.5)

65.2 (52.8, 77.6)

≥10

85.7 (42.1, 99.6)

1.6 (0.3, 4.6)

0.644 (0.41, 0.87)

STEC Cohort
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Abbreviations: AUC, area under the curve; CI, confidence interval; HUS, hemolytic uremic syndrome; STEC, Shiga toxin-producing Escherichia
coli
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